Transthyretin Amyloidosis Market

Key Players: Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Prothena Corporation (US), Akcea Therapeutics (US)

Transthyretin Amyloidosis Market

Transthyretin (TTR) Amyloidosis Market Research Report Information Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male &amp Female), Treatment (Small Molecule Treatment), and End-User (Ambulatory Surgical Center, Clinics) and Forecast Till 2035
ID: MRFR/Pharma/4697-HCR
100 Pages
Rahul Gotadki
Last Updated: May 15, 2026
Request Free Sample

Transthyretin Amyloidosis Market Summary

As per MRFR analysis, the Transthyretin Amyloidosis Market Size was estimated at 5.98 USD Billion in 2024. The Transthyretin Amyloidosis industry is projected to grow from 6.45 USD Billion in 2025 to 12.18 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.64% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Transthyretin Amyloidosis Market is experiencing significant growth driven by advancements in diagnosis and treatment options.

  • Rising awareness and diagnosis of Transthyretin Amyloidosis are enhancing patient identification, particularly in North America.
  • Advancements in therapeutic options are expanding treatment avenues, especially for Cardiac Amyloidosis, which remains the largest segment.
  • Personalized medicine approaches are gaining traction, with Neuropathic Amyloidosis emerging as the fastest-growing segment.
  • The increasing prevalence of Transthyretin Amyloidosis and innovative drug development are key drivers propelling market expansion in the Asia-Pacific region.

Market Size & Forecast

2024 Market Size 5.98 (USD Billion)
2035 Market Size 12.18 (USD Billion)
CAGR (2025 - 2035) 6.64%

Major Players

Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Prothena Corporation (US), Akcea Therapeutics (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Transthyretin Amyloidosis Market Trends

The Transthyretin Amyloidosis Market is currently experiencing notable developments, driven by a growing awareness of the disease and advancements in treatment options. This condition, characterized by the accumulation of amyloid proteins, has garnered increased attention from both healthcare professionals and patients. As a result, there is a rising demand for effective therapies and diagnostic tools. Pharmaceutical companies are actively engaged in research and development, aiming to introduce innovative solutions that address the complexities of this disorder. Furthermore, collaborations between various stakeholders, including academic institutions and biotech firms, appear to be fostering a more robust pipeline of potential treatments. In addition to therapeutic advancements, the Transthyretin Amyloidosis Market is witnessing a shift in patient management strategies. Healthcare providers are increasingly focusing on personalized medicine approaches, tailoring treatments to individual patient profiles. This trend suggests a move towards more effective and targeted therapies, which may enhance patient outcomes. Moreover, the integration of digital health technologies into patient care is likely to play a crucial role in monitoring disease progression and treatment efficacy. Overall, the market landscape is evolving, with a strong emphasis on innovation and patient-centric care, indicating a promising future for those affected by transthyretin amyloidosis.

Rising Awareness and Diagnosis

There is an increasing recognition of transthyretin amyloidosis among healthcare professionals and the general public. This heightened awareness is leading to improved diagnostic rates, enabling earlier intervention and better management of the disease.

Advancements in Therapeutic Options

The market is witnessing significant progress in the development of new therapies aimed at treating transthyretin amyloidosis. These advancements are driven by ongoing research and clinical trials, which are exploring various mechanisms of action to effectively target the underlying causes of the condition.

Personalized Medicine Approaches

A shift towards personalized medicine is becoming evident in the Transthyretin Amyloidosis Market. Tailoring treatment plans to individual patient needs is likely to enhance therapeutic outcomes and improve overall patient satisfaction.

Transthyretin Amyloidosis Market Drivers

Advancements in Therapeutic Options

Recent advancements in therapeutic options for transthyretin amyloidosis are poised to reshape the Global Transthyretin Amyloidosis Market Industry. Innovative treatments, including gene silencing therapies and monoclonal antibodies, have shown promising results in clinical trials. These developments are expected to enhance patient outcomes and potentially reduce the burden of the disease. As new therapies gain regulatory approval, the market is likely to witness a shift towards more effective treatment modalities. This evolution in therapeutic landscape is anticipated to contribute to the market's growth, with projections indicating a market size of 13.1 USD Billion by 2035.

Emerging Markets and Global Expansion

Emerging markets are playing a pivotal role in the expansion of the Global Transthyretin Amyloidosis Market Industry. As healthcare infrastructure improves in regions such as Asia-Pacific and Latin America, access to diagnostic and therapeutic options is increasing. This growth is further fueled by rising disposable incomes and a greater emphasis on healthcare spending. Pharmaceutical companies are strategically positioning themselves to tap into these markets, anticipating a surge in demand for transthyretin amyloidosis treatments. The global expansion of healthcare services is likely to create new opportunities for market players, contributing to the overall growth trajectory of the industry.

Growing Awareness and Education Initiatives

The Global Transthyretin Amyloidosis Market Industry benefits significantly from growing awareness and education initiatives aimed at both healthcare professionals and the general public. Increased understanding of the disease's symptoms and progression is crucial for early diagnosis and intervention. Organizations and advocacy groups are actively promoting educational campaigns, which are likely to lead to a higher rate of diagnosis and treatment. As awareness continues to expand, the market is expected to see a corresponding increase in demand for therapeutic options. This trend underscores the importance of collaborative efforts in enhancing knowledge about transthyretin amyloidosis.

Rising Investment in Research and Development

Investment in research and development within the Global Transthyretin Amyloidosis Market Industry is on the rise, driven by the urgent need for effective treatments. Pharmaceutical companies are increasingly allocating resources to explore novel therapeutic avenues, including small molecules and biologics. This commitment to innovation is crucial, as it not only addresses the unmet medical needs of patients but also fosters a competitive market environment. The anticipated compound annual growth rate of 7.63% from 2025 to 2035 reflects the industry's optimism regarding future breakthroughs. Enhanced funding for research initiatives is likely to accelerate the development of new therapies and improve patient care.

Increasing Prevalence of Transthyretin Amyloidosis

The Global Transthyretin Amyloidosis Market Industry is experiencing a notable surge in prevalence, with an estimated 5.85 USD Billion market valuation in 2024. This increase is attributed to heightened awareness and improved diagnostic capabilities, leading to earlier identification of the disease. As healthcare professionals become more adept at recognizing symptoms, the number of diagnosed cases is expected to rise significantly. This trend not only underscores the importance of effective treatment options but also highlights the necessity for ongoing research and development in this field. The growing patient population is likely to drive demand for innovative therapies and management strategies.

Market Segment Insights

By Application: Cardiac Amyloidosis (Largest) vs. Polyneuropathy (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the application segment is notably dominated by Cardiac Amyloidosis, which holds a significant market share due to its prevalence and serious health implications associated with the condition. Polyneuropathy, on the other hand, has emerged as a rapidly growing segment, leveraging advancements in treatment options and heightened awareness of the condition among healthcare providers and patients alike. Together, these segments reflect the nuanced landscape of the market, where differing patient needs and treatment possibilities drive varying levels of engagement and investment.

Cardiac Amyloidosis (Dominant) vs. Polyneuropathy (Emerging)

Cardiac Amyloidosis is recognized as the dominant application segment within the Transthyretin Amyloidosis Market, primarily due to its notable impact on patient morbidity and mortality rates. This condition often leads to severe cardiovascular complications, necessitating timely diagnosis and effective management strategies. In contrast, Polyneuropathy is positioned as an emerging segment, rapidly gaining traction as more patients are diagnosed with peripheral nerve involvement. Factors contributing to its growth include technological advancements in diagnostics and an increasing pipeline of therapies aimed at addressing neurological manifestations of amyloidosis. Both segments exhibit unique characteristics in terms of patient demographics and clinical management, shaping their respective trajectories in a competitive market.

By Diagnosis Method: Biopsy (Largest) vs. Imaging Techniques (Fastest-Growing)

In the Transthyretin Amyloidosis Market, various diagnosis methods play a crucial role in identifying the disease. Currently, the biopsy stands out as the largest segment, with a significant share due to its reliability and accuracy in confirming transthyretin amyloidosis through histological analysis of tissues. Imaging techniques, on the other hand, are rapidly gaining traction, reflective of the increasing emphasis on non-invasive diagnostic approaches. This shift is driven by advancements in technology that enhance the sensitivity and specificity of imaging modalities, leading to improved patient outcomes.

Imaging Techniques (Dominant) vs. Blood Tests (Emerging)

Imaging techniques are becoming increasingly dominant in the diagnosis of transthyretin amyloidosis as they offer non-invasive methods to visualize amyloid deposits in various organs. These techniques, including MRI and ultrasound, are pivotal in assessing disease progression and organ involvement. Conversely, blood tests represent an emerging segment, providing insights into biomarker levels indicative of the disease. While blood tests are becoming more sophisticated with advances in genetic and metabolic profiling, they still lag behind imaging modalities in accuracy and comprehensive assessment, positioning them as a vital complementary tool rather than a standalone diagnostic solution.

By Treatment Type: Pharmacological Therapy (Largest) vs. Gene Therapy (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the treatment landscape is primarily dominated by Pharmacological Therapy, which holds the largest market share due to its established efficacy and widespread acceptance among healthcare professionals. Supportive Care also plays a crucial role, providing essential management of symptoms, but remains secondary in market share. Gene Therapy and Stem Cell Transplantation represent emerging approaches, with Gene Therapy gaining traction as innovative solutions are developed that target the underlying causes of transthyretin amyloidosis directly.

Pharmacological Therapy (Dominant) vs. Gene Therapy (Emerging)

Pharmacological Therapy has long been the first line of treatment for transthyretin amyloidosis, offering a range of options, including tafamidis and diflunisal, which have proven effective in stabilizing the transthyretin protein. This segment is bolstered by ongoing clinical trials and enhancements in drug formulations. Conversely, Gene Therapy, while still in developmental stages, is seen as a groundbreaking advancement with the potential to cure the disease at the genetic level, showcasing significant promise due to technological advancements. Its ability to address root causes rather than just symptoms positions it as an exciting and rapidly evolving area in the treatment domain.

By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Transthyretin Amyloidosis Market, the patient demographics significantly influence therapeutic approaches and market dynamics. The Age Group segment represents the largest share, with older populations being more susceptible to this condition, consequently driving market demand towards age-appropriate treatment solutions. Gender, while traditionally less emphasized, is emerging as a crucial demographic factor, with a growing recognition of differences in disease manifestation and treatment responses between male and female patients. Growth trends within the Patient Demographics segment are being driven by an aging population and increasing awareness of Transthyretin Amyloidosis among healthcare providers. As life expectancy rises, more patients are diagnosed, particularly in elderly cohorts. Additionally, targeted campaigns focusing on gender-specific symptoms are rapidly gaining traction, highlighting the importance of inclusive research and development methods to cater effectively to both male and female patients, thus fostering market growth.

Age Group: 65+ (Dominant) vs. 45-64 (Emerging)

The Age Group segment highlights the dominance of patients aged 65 and older, as they are more frequently diagnosed with Transthyretin Amyloidosis due to the degenerative nature of the disease, which tends to manifest later in life. This older demographic shows a significant need for specialized care and treatment options, which shapes the market landscape. In contrast, the 45-64 age group is emerging as an important segment due to increased awareness and improvements in early diagnosis, leading to a growing number of patients seeking treatment. This younger cohort is likely to drive future innovations in therapy as they advocate for better management strategies and awareness surrounding Transthyretin Amyloidosis.

By Healthcare Setting: Hospitals (Largest) vs. Specialty Clinics (Fastest-Growing)

Within the Transthyretin Amyloidosis Market, hospitals represent the largest segment, capturing a significant share of the total market due to their comprehensive care capabilities and access to advanced treatment technologies. Specialty clinics, however, are emerging as the fastest-growing segment, benefiting from their focused expertise and targeted treatments that cater to the unique needs of patients suffering from transthyretin amyloidosis.

Healthcare Settings: Hospitals (Dominant) vs. Specialty Clinics (Emerging)

Hospitals remain the dominant force in the healthcare setting for transthyretin amyloidosis due to their extensive resources, including specialized medical personnel and treatment facilities. They provide broad-spectrum care from diagnosis to treatment and are equipped to handle complex cases. In contrast, specialty clinics are recognized as an emerging segment, offering personalized treatments and dedicated services tailored for transthyretin amyloidosis patients. Their specialized focus fosters innovation and attracts patients seeking targeted therapies, thus driving their rapid growth in the market.

Get more detailed insights about Transthyretin Amyloidosis Market
Request Free Sample

Regional Insights

North America : Leading Market Innovators

North America is poised to maintain its leadership in the Transthyretin Amyloidosis market, holding a significant market share of $3.0 billion in 2024. The region benefits from advanced healthcare infrastructure, increasing awareness of the disease, and a growing patient population. Regulatory support from agencies like the FDA has accelerated the approval of innovative therapies, driving demand for effective treatments. The competitive landscape is robust, with key players such as Alnylam Pharmaceuticals, Pfizer, and Bristol-Myers Squibb leading the charge. These companies are heavily investing in research and development to enhance treatment options. The presence of established healthcare systems and a focus on patient-centric care further solidify North America's position as a market leader.

Europe : Emerging Treatment Landscape

Europe is witnessing a burgeoning Transthyretin Amyloidosis market, projected to reach $1.8 billion by 2025. The region's growth is driven by increasing healthcare expenditure, heightened awareness of rare diseases, and supportive regulatory frameworks. Initiatives from the European Medicines Agency (EMA) are facilitating faster access to innovative therapies, thereby enhancing treatment availability for patients. Leading countries such as Germany, France, and the UK are at the forefront of this market, with a strong presence of pharmaceutical giants like Pfizer and Bristol-Myers Squibb. The competitive landscape is characterized by strategic collaborations and partnerships aimed at advancing research. The focus on personalized medicine and patient access programs is expected to further propel market growth.

Asia-Pacific : Emerging Market Potential

The Asia-Pacific region is emerging as a significant player in the Transthyretin Amyloidosis market, with a projected market size of $0.9 billion by 2025. Factors such as increasing healthcare investments, rising awareness of amyloidosis, and improving diagnostic capabilities are driving market growth. Regulatory bodies are also beginning to recognize the need for expedited approvals for rare disease treatments, which is expected to enhance market dynamics. Countries like Japan and Australia are leading the charge, with key players such as Eisai Co., Ltd. and Amgen Inc. actively participating in the market. The competitive landscape is evolving, with a focus on local partnerships and collaborations to enhance treatment accessibility. As healthcare systems improve, the region is likely to see a surge in demand for effective therapies.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents an untapped market for Transthyretin Amyloidosis, with a market size of $0.28 billion projected by 2025. The growth is driven by increasing healthcare investments and a rising prevalence of rare diseases. However, challenges such as limited access to healthcare and regulatory hurdles remain. Governments are beginning to prioritize rare disease initiatives, which could catalyze market development. Countries like South Africa and the UAE are showing potential, with a growing interest from pharmaceutical companies. The competitive landscape is still developing, with local and international players exploring opportunities. As awareness and healthcare infrastructure improve, the region is expected to gradually embrace innovative treatment options.

Transthyretin Amyloidosis Market Regional Image

Key Players and Competitive Insights

The Transthyretin Amyloidosis Market is characterized by a dynamic competitive landscape, driven by increasing awareness of the disease and advancements in therapeutic options. Key players such as Alnylam Pharmaceuticals (US), Pfizer (US), and Bristol-Myers Squibb (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Alnylam Pharmaceuticals (US) focuses on innovation through its RNA interference technology, which has shown promise in treating hereditary transthyretin amyloidosis. Meanwhile, Pfizer (US) emphasizes strategic partnerships to bolster its research capabilities and expand its product pipeline. Bristol-Myers Squibb (US) is leveraging its extensive experience in oncology to explore novel treatment avenues for transthyretin amyloidosis, indicating a trend towards cross-disciplinary approaches in drug development.The market structure appears moderately fragmented, with several players vying for dominance. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is particularly evident as firms seek to mitigate risks associated with global supply chain disruptions. The collective influence of these key players shapes a competitive environment where innovation and operational efficiency are paramount.

In November Alnylam Pharmaceuticals (US) announced a collaboration with a leading biotechnology firm to accelerate the development of its next-generation therapies for transthyretin amyloidosis. This strategic move is likely to enhance Alnylam's research capabilities and expedite the delivery of innovative treatments to patients, reinforcing its position as a leader in the market. The collaboration underscores the importance of partnerships in driving innovation and addressing unmet medical needs.

In October Pfizer (US) launched a new initiative aimed at increasing patient access to its transthyretin amyloidosis therapies in emerging markets. This initiative includes educational programs for healthcare professionals and patients, which may significantly enhance treatment uptake. By focusing on access and education, Pfizer is not only expanding its market reach but also contributing to improved patient outcomes, which is increasingly recognized as a critical factor in the pharmaceutical industry.

In September Bristol-Myers Squibb (US) completed the acquisition of a small biotech firm specializing in amyloidosis research. This acquisition is expected to bolster Bristol-Myers Squibb's pipeline and enhance its capabilities in developing targeted therapies. The strategic importance of this move lies in the potential to integrate innovative research into its existing portfolio, thereby accelerating the development of new treatment options for patients suffering from transthyretin amyloidosis.

As of December current competitive trends in the Transthyretin Amyloidosis Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to deliver cutting-edge therapies and ensure patient access, thereby fostering a more sustainable and patient-centric market environment.

Key Companies in the Transthyretin Amyloidosis Market include

Industry Developments

Pfizer has received FDA approval for Vyndaqel (tafamidis) as a treatment for wild-type ATTR amyloidosis, based on clinical data showing significant benefits in reducing cardiac complications.

July 2024

Ionis has introduced IONIS-TTR-LRx, a new antisense oligonucleotide drug, with promising clinical trials indicating stronger efficacy and improved safety compared to existing therapies.

Transthyretin Amyloidosis Market is a progressive disease that includes an abnormal buildup of abnormal proteins under the skin or in organs like kidneys, heart, eyes, brain, or tissues. The diseases have implications for organs and the peripheral nervous system. There are two presentations of the condition which are Transthyretin amyloid polyneuropathy and Transthyretin amyloid cardiomyopathy. 

In Transthyretin amyloid polyneuropathy, the amyloid fibrils are deposited in the peripheral nervous system and Transthyretin Amyloid cardiomyopathy, the deposits are made on the heart which could lead to heart failure. The type of the condition is majorly dependent on the type of protein that is deposited in the organs. 

The symptoms could get worse over time and varies according to the protein deposits. Amyloid buildup in the nerves can permanently affect the nervous system and eventually loss of sensation in limbs, hands, and feet. Although they primarily affect the voluntary functions of the patients, they tend to affect the involuntary body functions such as blood pressure, heart rate, digestion, and so on. The survival chances are only 7 years from the disease onset. These factors are primarily responsible for the overall growth of the Transthyretin Amyloidosis Market.

COVID 19 Analysis:

The pandemic has significantly affected major health concerns and various other health sectors. The physicians have tries different methods in assisting patients to offer a potential treatment. Especially physicians have found it very challenging in handling COVID-infected ATTR patients. Since Transthyretin Amyloidosis Market is a progressive disease, they tend to develop multi-organ complications due to COVID infection.

The delays in the diagnosis and interrupted treatment due to movement restrictions across several countries have inflicted significant risks for the patients with Transthyretin Amyloidosis Market. Additionally, patients and doctors found the changing trend of the treatment procedure, while ensuring to reduce the interruptions in treatments.

Future Outlook

Transthyretin Amyloidosis Market Future Outlook

The Transthyretin Amyloidosis Market is projected to grow at a 6.64% CAGR from 2025 to 2035, driven by advancements in therapies, increasing awareness, and improved diagnostic techniques.

New opportunities lie in:

  • Development of targeted gene therapies for hereditary forms
  • Expansion of telehealth services for remote patient monitoring
  • Partnerships with diagnostic companies for early detection solutions

By 2035, the market is expected to achieve substantial growth and innovation.

Market Segmentation

Transthyretin Amyloidosis Market Application Outlook

  • Cardiac Amyloidosis
  • Neuropathic Amyloidosis
  • Ocular Amyloidosis
  • Cerebral Amyloidosis

Transthyretin Amyloidosis Market Treatment Type Outlook

  • Pharmacological Therapy
  • Supportive Care
  • Gene Therapy
  • Stem Cell Transplantation

Transthyretin Amyloidosis Market Diagnosis Method Outlook

  • Biopsy
  • Genetic Testing
  • Imaging Techniques
  • Blood Tests

Transthyretin Amyloidosis Market Healthcare Setting Outlook

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Research Institutions

Transthyretin Amyloidosis Market Patient Demographics Outlook

  • Age Group
  • Gender
  • Genetic Predisposition
  • Comorbid Conditions

Report Scope

MARKET SIZE 2024 5.98(USD Billion)
MARKET SIZE 2025 6.45(USD Billion)
MARKET SIZE 2035 12.18(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.64% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Ionis Pharmaceuticals (US), Eisai Co., Ltd. (JP), Amgen Inc. (US), Prothena Corporation (US), Akcea Therapeutics (US)
Segments Covered Application, Diagnosis Method, Treatment Type, Patient Demographics, Healthcare Setting
Key Market Opportunities Advancements in gene therapies and novel therapeutics enhance treatment options in the Transthyretin Amyloidosis Market.
Key Market Dynamics Rising demand for innovative therapies drives competitive dynamics in the Transthyretin Amyloidosis market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Transthyretin Amyloidosis Market?

As of 2024, the Transthyretin Amyloidosis Market was valued at 5.98 USD Billion.

What is the projected market size for the Transthyretin Amyloidosis Market by 2035?

The market is projected to reach 12.18 USD Billion by 2035.

What is the expected CAGR for the Transthyretin Amyloidosis Market during the forecast period?

The expected CAGR for the Transthyretin Amyloidosis Market from 2025 to 2035 is 6.64%.

Which companies are the key players in the Transthyretin Amyloidosis Market?

Key players include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Ionis Pharmaceuticals, Eisai Co., Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Horizon Therapeutics.

What are the main applications of treatments in the Transthyretin Amyloidosis Market?

The main applications include Cardiac Amyloidosis, Polyneuropathy, Cerebral Amyloidosis, and Ocular Amyloidosis, with valuations ranging from 1.07 to 4.25 USD Billion.

How is the Transthyretin Amyloidosis Market segmented by diagnosis method?

The market is segmented into Biopsy, Imaging Techniques, Blood Tests, and Genetic Testing, with values from 1.0 to 3.66 USD Billion.

What treatment types are included in the Transthyretin Amyloidosis Market?

Treatment types include Pharmacological Therapy, Supportive Care, Gene Therapy, and Stem Cell Transplantation, with valuations between 1.19 and 4.88 USD Billion.

How does patient demographics affect the Transthyretin Amyloidosis Market?

The market considers factors like Age Group, Gender, Genetic Predisposition, and Comorbid Conditions, with valuations from 1.19 to 3.65 USD Billion.

What healthcare settings are involved in the Transthyretin Amyloidosis Market?

Healthcare settings include Hospitals, Specialty Clinics, Home Healthcare, and Research Institutions, with values ranging from 0.9 to 4.85 USD Billion.

What trends are anticipated in the Transthyretin Amyloidosis Market by 2035?

By 2035, the market is likely to experience growth driven by advancements in treatment options and increased awareness of the disease.
Author
Author
Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

Primary Research

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, chief medical officers, vice presidents of clinical development, heads of regulatory affairs, and commercial directors from pharmaceutical companies creating TTR-targeted treatments (such as RNAi medicines, antisense oligonucleotides, and small molecule stabilizers) were examples of supply-side sources. Board-certified cardiologists, neurologists, genetic counselors, medical directors of amyloidosis treatment facilities, and procurement leads from university medical institutions, specialty amyloidosis clinics, and hospital pharmacy departments were examples of demand-side sources. Primary research verified drug pipeline timings, validated disease segmentation (hereditary vs. wild-type ATTR), and acquired information on treatment uptake trends, pricing tactics, reimbursement dynamics, and patient identification programs.

Primary Respondent Breakdown:

By Designation: C-level Primaries (40%), Director Level (25%), Others (35%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping and patient volume analysis. The methodology included:

Identification of 35+ key pharmaceutical companies across North America, Europe, Asia-Pacific, and Latin America developing TTR-targeted therapies

Product mapping across small molecule stabilizers (tafamidis), RNA interference therapeutics (patisiran, vutrisiran), antisense oligonucleotides (eplontersen), and emerging gene editing therapies

Analysis of reported and modeled annual revenues specific to transthyretin amyloidosis portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (diagnosed prevalent patient population × treatment penetration rate × annual therapy cost by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across cardiac amyloidosis, polyneuropathy, and other clinical manifestations

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.